*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2025 | The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI Nature communications · preclinical | PMID 40593617 |
| 2025 | Peptide Inhibitors Targeting FOXO4-p53 Interactions and Inducing Senescent Cancer Cell-specific Apoptosis Journal of medicinal chemistry · preclinical | PMID 40739602 |
| 2025 | FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation Communications biology · preclinical | PMID 39994346 |
| 2025 | Structural plasticity of the FOXO-DBD:p53-TAD interaction Nature communications · preclinical | PMID 40425537 |
| 2024 | FOXO transcription factors as mediators of stress adaptation Nature reviews. Molecular cell biology · preclinical | PMID 37710009 |
| 2023 | Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression Circulation · preclinical | PMID 36515093 |
| 2022 | FOXO transcription factors as therapeutic targets in human diseases Trends in pharmacological sciences · preclinical | PMID 36280450 |
| 2021 | Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis JCI insight · preclinical | PMID 34877934 |
| 2017 | Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging Cell · preclinical | PMID 28340339 |
| 2016 | Long live FOXO: unraveling the role of FOXO proteins in aging and longevity Aging cell · preclinical | PMID 26643314 |
FOXO4-DRI (FOXO4-DRI (D-retro-inverso FOXO4 peptide; senolytic)). D-retro-inverso peptide that disrupts the FOXO4–p53 interaction in senescent cells, selectively triggering apoptosis of senescent cells (senolytic) in preclinical models.
Commonly discussed uses: senescence/longevity research (preclinical). The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Note: most uses are not approved indications.
Mechanism: D-retro-inverso peptide that disrupts the FOXO4–p53 interaction in senescent cells, selectively triggering apoptosis of senescent cells (senolytic) in preclinical models.
Reported considerations: no human safety data, theoretical: broad apoptotic effects, renal stress in animal studies. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Preclinical only. No human safety data. High-uncertainty research compound. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low research-defined, typical no established human dose; unvalidated anecdotal protocols exist, high unknown safe ceiling. Administration: intravenous/intraperitoneal (animal studies), subcutaneous (anecdotal, unvalidated). Half-life: not characterised in humans.
Australian status: Not ARTG-registered; research. Preclinical only. No human safety data. High-uncertainty research compound. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: research-defined; storage: frozen aliquots.
Commonly discussed combinations (anecdotal for unapproved compounds): experimental; no validated human protocol. Stacking increases interaction/safety uncertainty.